Clinical results including hemodynamic performance of the Medtronic Mosaic porcine bioprosthesis up to ten years
The main advantage of bioprosthetic cardiac valves in comparison to mechanical prosthesis is the lower incidence of antithromboembolic-related hemorrhages. However, bioprostheses have limited durability due to progressive tissue degeneration and calcification resulting in structural valve deterioration (SVD) and suboptimal hemodynamic performances. The Medtronic Mosaic bioprosthesis is a supraannular third-generation stented porcine bioprosthesis which was introduced in 1994. It is built upon the historical durability of the Hancock II valve  and technical innovations were incorporated into the design in an attempt to improve hemodynamic performance and durability . Tissue fixation with the Medtronic Physiologic Fixation™ process is performed with glutaraldehyde in order to minimize the consequences of antigenicity after porcine valve implantation . Furthermore, the valve design includes predilatation of the porcine aortic root and using zero net pressure across the leaflets (Fig. 1a) . By this treatment, natural leaflet morphology is generally preserved. The tissue is mounted on a low-profile flexible polymer stent (Fig. 1b) to minimize hemodynamic disturbance and to make it suitable for patients with small aortic root diameters.
KeywordsAfter Mosaic Valve Replacement Mitral Valve Replacement Effective Orifice Area Paravalvular Leak Hemodynamic Performance
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Unable to display preview. Download preview PDF.
- 3.Carpentier A, Lemaigre G, Robert L, Carpentier S, Dubost C (1969) Biological factors affecting long-term results of valvular heterografts. J Thorac Cardiovas Surg 58:467Google Scholar
- 4.Vesley I (1991) Analysis of the Medtronic Intact bioprosthesis valve. Effects of zero-pressure fixation. J Thorac Cardiovasc Surg 101:90–99Google Scholar
- 6.Girardot MN, Girardot JM, Schoen FJ (1991) Alpha amino oleic acid, a new compound, prevents calcification of bioprosthetic heart valves. Trans Soc Biomater 14:114–116Google Scholar
- 10.Salomon NW, Okies JE, Krause AH, Page US, Bigelow JC, Colburn LQ (1991) Serial follow-up of an experimental bovine pericardial aortic bioprosthesis. Circulation 84:140–144Google Scholar
- 25.Pelletier LC, Carrier M, Leclerc Y, Dyrda I (1995) The Carpentier-Edwards pericardial bioprosthesis: clinical experience with 600 patients. Ann Thorac Surg 60 (2 Suppl): 297–302Google Scholar
- 28.Akins CW, Carroll DL, Buckley MJ, Daggett WM, Hilgenberg AD, Austen WG (1990) Late results with Carpentier-Edwards porcine bioprosthesis. Circulation 82(Suppl IV):65–74Google Scholar
- 34.Gansera B, Botzenhardt F, Grünzinger R, Spiliopoulos K, Angelis I, Kemkes BM (2003) The Mosaic bioprosthesis in aortic position: seven years’ results. J Heart Valve Disease 12:354–361Google Scholar
© Springer-Verlag Berlin Heidelberg 2010